Plasma fractionation refers to the general process of separating the various components of blood plasma. It involves breaking down plasma into individual proteins, also called plasma fractions. Plasma fractionation was initially developed in the 1940s to isolate serum albumin fraction from the blood plasma.
Over the years, the procedure’s scope has expanded and can now be used to extract 20 different proteins. With increasing blood-related disorders and the growing prevalence of infectious diseases, the plasma fractionation market is expanding and expected to maintain a steady growth rate over the forecast period.
How is Plasma Obtained?
Obtaining the plasma can be done in one of the following two ways:
Whole blood (recovered plasma): This plasma is obtained through whole blood donation. Here, the donated whole blood is separated into cellular components using a process called apheresis.
Apheresis (source plasma): This medical procedure removes whole blood from a patient. The removed whole blood is then separated into individual components to facilitate the removal of one particular component. After removing the specific component, other blood components are re-introduced back into the donor’s bloodstream.
Market Analysis and Growth Drivers
According to a new study by Polaris Market Research and Consulting, the plasma fractionation market was valued at USD 25.55 billion in 2022 and is expected to grow at a CAGR of 6.8%, generating an estimated revenue of USD 45.11 billion by 2030.
The market is primarily driven by increasing collaboration between governments and corporate entities and growing emphasis on R&D initiatives in various industries. Numerous awareness programs are being conducted to encourage people to donate blood. Besides, initiatives are being undertaken to create awareness about using fractionation therapy-based products.
The rising cases of infectious diseases among the geriatric population worldwide have led to increased R&D initiatives in the industry. The development of new treatment methods, along with other technological advancements, is expected to boost the market’s growth.
Common Plasma Proteins Listed
Plasma contains a large variety of proteins. Below, we’ve listed the common plasma proteins large-scale manufacturers are especially focused on:
Albumin: Albumin makes up about 60% of the total protein in plasma. It’s a vital component of trauma medicine widely used in trauma cases involving large fluid loss.
Immunoglobulins: Immunoglobulins, or antibodies, are a Y-shaped protein formed when the body is recovering from an infectious organism’s attack. It helps spot and neutralize pathogenic viruses and bacteria in the body.
Coagulation factors: These are proteins present in the human blood. Coagulation factors are produced by the liver, and they help form blood clots to stop bleeding after experiencing an injury. They are also used to treat blood clotting disorders like hemophilia and von Willebrand’s disease.
Immunoglobin Segment Accounted for the Largest Market Share
By product plasma fractionation market segmentation, the immunoglobin segment held the largest market share in 2021. This is largely due to immunoglobin-based products in treating immunodeficiency disorders. Immunoglobin is known for its numerous advantages in drug applications, including immunosenescence, curing, and immunity-based changes. With the rising prevalence of infectious diseases, the use of immunoglobin products is expected to rise in the upcoming years.
Regional Analysis
North America: North America is the dominant region with the highest share in the market. This is primarily because of rising respiratory ailments and increasing respiratory disorders among people in the region. Other factors influencing the region’s growth are the presence of plasma fractionation market key players, the growing number of blood collection units, and rising immunoglobin consumption in North America.
Asia Pacific: The market for plasma fractionation is expected to expand in Asia Pacific due to rising R&D investments from private, public, and government entities and an aging population with blood-related disorders. Besides, growing target disease prevalence and increased immunoglobulin use impact the region’s growth favorably.
Treating Blood-Related Disorders
To conclude, plasma fractionation segregates plasma derivatives with numerous applications in the biotechnology and pharmaceutical sectors. The increasing geriatric population and rising R&D investments across various sectors drive the plasma fractionation market growth.